A Phase I/II Study of Glembatumumab Vedotin in Patients With gpNMB-Expressing, Advanced or Metastatic Squamous Cell Carcinoma of the Lung

Trial Profile

A Phase I/II Study of Glembatumumab Vedotin in Patients With gpNMB-Expressing, Advanced or Metastatic Squamous Cell Carcinoma of the Lung

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Glembatumumab vedotin (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors PrECOG
  • Most Recent Events

    • 10 Mar 2017 Planned number of patients changed from 49 to 52.
    • 18 Apr 2016 Status changed from not yet recruiting to recruiting.
    • 22 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top